BIOSINO BIO-TEC (08247) nominated Kang Rui as a non-executive director.
Zhongsheng Beikong Biotechnology (08247) announced that Mr. Yang Peng, Dr. Gao Guangxia, Dr. Shen Sheng, Professor Shen Zuojun, and Dr. He Xin will not stand for re-election due to their desire to invest more time in other matters.
BIOSINO BIO-TEC (08247) announced that Mr. Yang Peng, Dr. Gao Guangxia, Dr. Shen Sheng, Professor Shen Zuojun, and Dr. He Xin will not seek reelection due to their desire to devote more time to other matters.
The board of directors has proposed to reappoint the remaining directors as members of the Ninth Board of Directors (subject to approval at a special shareholders' meeting). The details are as follows: reappoint Mr. Chen Zhengyong, the current executive director, as an executive director of the Ninth Board of Directors; reappoint Mr. Li Zhonghua, the current executive director, as an executive director of the Ninth Board of Directors; reappoint Mr. Chen Peng, the current executive director, as an executive director of the Ninth Board of Directors; reappoint Professor Shen Jiangan, the current independent non-executive director, as an independent non-executive director of the Ninth Board of Directors; and reappoint Mr. Fan Xiaoliang, the current independent non-executive director, as an independent non-executive director of the Ninth Board of Directors.
The following individuals have been nominated as directors of the Ninth Board of Directors, subject to approval at a special shareholders' meeting: appoint Ms. Kang Rui as a non-executive director of the Ninth Board of Directors; and appoint Professor Jin Tengchuan as an independent non-executive director of the Ninth Board of Directors.
Upon the conclusion of the special shareholders' meeting, the members of the audit committee, nomination committee, and remuneration committee under the Ninth Board of Directors are as follows: Chairman of the Audit Committee: Mr. Fan Xiaoliang, Members: Professor Shen Jiangan and Professor Jin Tengchuan; Chairman of the Nomination Committee: Professor Jin Tengchuan, Members: Mr. Fan Xiaoliang and Professor Shen Jiangan; Chairman of the Remuneration Committee: Professor Shen Jiangan, Members: Mr. Fan Xiaoliang and Professor Jin Tengchuan.
Related Articles

CHAOJU EYE CARE (02219) spent 163,300 Hong Kong dollars to repurchase 60,000 shares on January 22nd.

Hengyi Petrochemical (000703.SZ) plans to spend 500 million to 1 billion yuan to implement a buyback.

CLARITY MEDICAL(01406): XU Anliang appointed as independent non-executive director and member of the audit committee.
CHAOJU EYE CARE (02219) spent 163,300 Hong Kong dollars to repurchase 60,000 shares on January 22nd.

Hengyi Petrochemical (000703.SZ) plans to spend 500 million to 1 billion yuan to implement a buyback.

CLARITY MEDICAL(01406): XU Anliang appointed as independent non-executive director and member of the audit committee.

RECOMMEND

Paul Chan Says Hong Kong Has Licensed 11 Virtual Asset Exchanges, Stablecoin Licenses Expected Later This Year
22/01/2026

Ministry Of Finance And Other Departments Introduce Comprehensive Fiscal And Financial Policies To Boost Domestic Demand
22/01/2026

Capital Migration: Five Years On, An In‑Depth Analysis Of China’s 11 High‑Growth Venture Capital Tracks In 2025
22/01/2026


